This page covers Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease.
Title: Metal Ion-Synuclein-Mitochondria Axis Validation in Parkinson's Disease
Hypothesis Tested: The Metal Ion-Synuclein-Mitochondria (MISM) Axis Hypothesis - that dysregulated iron and copper homeostasis in dopaminergic neurons creates a convergent pathological environment promoting alpha-synuclein aggregation AND mitochondrial dysfunction through oxidative stress.
Primary Objective: Validate the causal relationship between metal ion dyshomeostasis, alpha-synuclein aggregation, and mitochondrial dysfunction in PD patient-derived models.
Secondary Objectives:
- Identify optimal biomarkers for metal dysregulation in PD
- Test therapeutic modulation of metal homeostasis
- Characterize genotype-phenotype interactions
Model System: Recombinant alpha-synuclein protein, iPSC-derived dopaminergic neurons
Experimental Groups:
- Control (no metal addition)
- Fe(III) treatment (various concentrations: 1, 5, 10, 25 μM)
- Cu(II) treatment (various concentrations: 0.1, 0.5, 1, 5 μM)
- Fe(III) + Cu(II) combination
- Iron chelator (deferoxamine) + metal
- Antioxidant (N-acetylcysteine) + metal
Readouts:
- ThT fluorescence kinetics (aggregation rate)
- TEM imaging (fibril morphology)
- SDS-PAGE/Western blot (oligomer species)
- Atomic force microscopy (fibril structure)
Model System: iPSC-derived dopaminergic neurons from PD patients and healthy controls
Treatments:
- Iron overload (ferric ammonium citrate: 10, 50, 100 μM)
- Copper overload (copper sulfate: 1, 5, 10 μM)
- Iron chelation (deferoxamine: 50 μM)
- Combination treatments
Readouts:
- Seahorse XF analysis (OCR, ATP production)
- MitoSOX imaging (mitochondrial ROS)
- Mitochondrial membrane potential (TMRE)
- Complex I-V activities
- mtDNA copy number
Readouts:
- 8-OHdG (DNA oxidation) - immunostaining, ELISA
- 4-HNE (lipid peroxidation) - Western blot, mass spectrometry
- Protein carbonylation - OxyBlot assay
- GSH/GSSG ratio - HPLC
- Catalase, SOD activities - enzymatic assays
Models:
- C57BL/6J wild-type + MPTP lesion
- A53T alpha-synuclein transgenic mice
- HFE knockout mice (iron overload model)
- Cross: A53T × HFE-/-
Treatment Groups (n=15 per group):
- Vehicle control
- Iron chelator (deferoxamine: 50 mg/kg/day, IP)
- Copper chelator (trientine: 100 mg/kg/day, IP)
- Combination (deferoxamine + trientine)
- Antioxidant (CoQ10: 100 mg/kg/day, oral)
- Positive control: MAO-B inhibitor (selegiline)
Endpoints (12 weeks):
- Behavioral: Rotarod, cylinder test, gait analysis
- Histology: TH+ neuron count, iron staining (Perls), alpha-synuclein aggregation (pSer129)
- Biochemistry: Mitochondrial function, oxidative stress markers
- MRI: Quantitative susceptibility mapping (QSM) for iron
Viral Vector Approaches:
- AAV-FTH1 (ferritin heavy chain) overexpression
- AAV-CP (ceruloplasmin) overexpression
- shRNA targeting DMT1 (divalent metal transporter)
Participants:
- Early-stage PD (n=100)
- Prodromal PD (n=50)
- Healthy controls (n=100)
Biomarkers:
- Serum: Ferritin, transferrin, ceruloplasmin, hepcidin
- CSF: Iron, copper, ferritin, alpha-synuclein, oxidative stress markers
- Imaging: QSM-MRI for brain iron, R2* for substantia nigra
Correlations:
- Biomarker levels vs. MDS-UPDRS scores
- Biomarker levels vs. disease duration
- Biomarker levels vs. genetic status (GBA, LRRK2, SNCA)
Design: Randomized, double-blind, placebo-controlled
Intervention:
- Treatment: Deferasirox (30 mg/kg/day oral)
- Duration: 12 months
- Sample size: n=60 per arm
Primary Endpoint:
- Change in MDS-UPDRS Part III (motor) score
Secondary Endpoints:
- CSF biomarkers (iron, alpha-synuclein, oxidative stress)
- QSM-MRI brain iron
- Timed Up and Go test
- Quality of Life (PDQ-39)
In vitro:
- Power: 0.80, α = 0.05
- Expected effect size: 30% reduction in aggregation with chelation
- n = 3 replicates × 6 conditions = 18 per experiment
Animal:
- Power: 0.80, α = 0.05
- Expected effect: 25% improvement in behavioral scores
- n = 15 per group (6 groups = 90 total)
Clinical:
- Power: 0.80, α = 0.05
- Expected difference: 4 points on MDS-UPDRS
- n = 60 per arm (120 total)
- ANOVA with Tukey post-hoc for multiple comparisons
- Linear mixed models for longitudinal data
- Correlation analysis (Pearson/Spearman)
- Kaplan-Meier for progression analysis
- Machine learning for biomarker panel optimization
- Iron chelation: Anemia, retinal toxicity (monitor hemoglobin, eye exams)
- Animal models: Standard toxicology endpoints
- Clinical trial: Iron deficiency, organ dysfunction
- Close monitoring of iron parameters
- Stopping rules for safety
- Data safety monitoring board
| Phase |
Item |
Cost (USD) |
| Phase 1 |
iPSC differentiation, reagents |
$200,000 |
| Phase 1 |
Animal studies |
$300,000 |
| Phase 2 |
Biomarker cohort |
$150,000 |
| Phase 2 |
Clinical trial (preclinical) |
$500,000 |
| Phase 3 |
Pilot clinical trial |
$2,000,000 |
| Total |
|
$3,150,000 |
| Milestone |
Target Date |
| Phase 1 start |
Month 1 |
| Phase 1 complete |
Month 12 |
| Phase 2 start |
Month 10 |
| Phase 2 complete |
Month 36 |
| Biomarker cohort complete |
Month 30 |
| Clinical trial start |
Month 24 |
| Final analysis |
Month 48 |
-
Validation of MISM axis: Demonstrate that metal dysregulation is a primary driver of both alpha-synuclein aggregation and mitochondrial dysfunction
-
Biomarker panel: Identify serum/CSF biomarkers that predict PD progression
-
Therapeutic target: Establish metal modulation as a viable therapeutic strategy
- Mechanistic insights: Characterize iron-copper interaction in dopaminergic neurons
- Genetic modifiers: Identify patients who would benefit most from metal-targeted therapy
- Combination therapy: Develop optimized treatment protocols